Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.05%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.28 per share when it actually produced a loss of $0.24, delivering a surprise of 14.29%.Over the last four quar ...

临床试验 - 公司启动ATI-2138的2a期临床试验,研究其在中重度特应性皮炎中的安全性、耐受性、药代动力学、疗效和药效学[5] 许可协议 - 公司完成了与OMERS的OLUMIANT®版权交易,获得2650万美元的预付款,最高可获得500万美元的销售里程碑付款[6] - 第二季度许可费用130万美元,较上年同期增加70万美元,主要由于利利公司许可协议下的版税增加[11] 财务状况 - 公司预计截至2024年6月30日的现金、现金等价物和可用证券将足以为其运营提供资金,直至2028年,不包括任何潜在的新业务发展交易、额外融资活动或战略评估的结果[6] - 第二季度净亏损1100万美元,较上年同期减少1860万美元[7] - 第二季度总收入2760万美元,较上年同期增加890万美元,主要由于利利公司许可协议下的版税收入增加[8] - 第二季度研发费用880万美元,较上年同期减少1650万美元,主要由于zunsemetinib、lepzacitinib和ATI-2138的开发费用下降[9] - 第二季度一般及行政费用480万美元,较上年同期减少350万美元,主要由于员工人数减少和更高的放弃费用[10] - 第二季度或有对价重估产生20万美元的损失,而上年同期产生150万美元的收益[12]

-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities ...

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® ...

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris’ future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT ...

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume. The three biopharmaceutical stocks on this list have catalysts for higher share prices ranging from insider buying to product launches, their growth outlook, and analysts' sentiment. The question is whether they are worth buying to ...

财务数据和关键指标变化 - 公司维持了强劲的现金头寸,截至第一季度末现金、现金等价物和可流通证券为1.61亿美元,较年末的1.82亿美元有所下降 [1] - 公司在第一季度的总现金支出中,约有1400万美元为非经常性支出,包括已终止的研发项目、裁员相关的遣散费以及与孙公司许可协议相关的预付款 [1] - 公司预计未来几个季度的季度现金支出将大幅减少,不考虑任何潜在的业务发展交易 [1] 各条业务线数据和关键指标变化 - 公司决定将ATI-2138的首个适应症调整为中重度特应性皮炎,放弃之前计划的溃疡性结肠炎适应症 [2][3] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - ATI-2138是一种兼具ITK和JAK3抑制作用的潜在最佳化合物,具有独特的药理学特征和最佳in class的潜力 [2][3] - 公司正在扩展ITK通路的研究,专注于开发下一代选择性ITK抑制剂,以解决之前ATP竞争性抑制剂存在的问题 [3] - ITK抑制剂有望成为治疗多种自身免疫性疾病的有效口服药物,如特应性皮炎等Th2和Th17细胞驱动的疾病 [3] 管理层对经营环境和未来前景的评论 - 公司认为特应性皮炎是一个未被充分满足的市场,现有生物药和JAK抑制剂仍有较大改善空间,ATI-2138有望成为一种有效的口服替代疗法 [7] - 公司正在评估各种战略选择,未来将提供更多更新信息 [4] 问答环节重要的提问和回答 问题1 **Roger Song 提问** 询问ATI-2138抑制ITK和JAK3的协同/叠加效果,以及是否单独评估过这两个通路 [4][5] **Neal Walker 和 Joe Monahan 回答** - 公司在前期动物模型中观察到,同时抑制ITK和JAK3可以产生更强的抗炎作用,这是ATI-2138的一大优势 [4][5] - 公司还比较过选择性JAK3抑制剂ritlecitinib,发现ATI-2138在相同剂量和暴露下具有更好的抗炎活性 [5] 问题2 **Thomas Smith 提问** 询问ATI-2138与选择性JAK1抑制剂upadacitinib在特应性皮炎适应症上的比较 [5][6] **Neal Walker 回答** - 公司认为ATI-2138的ITK抑制作用是关键因素,可以直接作用于IL-4、IL-5等Th2细胞因子,从而给JAK3抑制带来协同增强作用 [6] - 公司希望ATI-2138能够优于upadacitinib,但需要通过临床试验进一步验证 [6] 问题3 **Gavin Clark-Gartner 提问** 询问医生如何看待ATI-2138相比其他JAK抑制剂的安全性概况 [7] **Neal Walker 回答** - 尽管ATI-2138可能也需要黑框警示,但公司认为这并不会成为太大障碍,因为患者更关注疾病能否得到快速缓解 - 公司观察到,即使有黑框警示,现有JAK抑制剂如baricitinib和RINVOQ在适应症如斑秃和特应性皮炎中仍取得了良好的增长 [7]

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.37 per share when it actually produced a loss of $0.30, delivering a surprise of 18.92%.Over the last four quar ...

Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37581 Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-0571712 ...

Exhibit 99.1 Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a co ...